Monday, June 01, 2020 5:28:36 PM
GlobeNewswire GlobeNewswireMarch 27, 2020
AUSTIN, Texas, March 27, 2020 (GLOBE NEWSWIRE) -- Vermillion, Inc. (VRML), a bioinformatics-based women’s health company focused on gynecologic disease, announced yesterday that its wholly owned subsidiary, ASPiRA Labs, has signed a national preferred agreement with Cigna. This contract includes OVA1, (Multivariate Index Assay, MIA) our ACOG endorsed ovarian cancer risk assessment test, as well as Overa and all genetic testing offered by ASPiRA. This agreement with Cigna will expand ASPiRA Labs contracted coverage by an additional 16 million lives.
“We are excited to add one of the major national payers to the ASPiRA contracted payer network, allowing another 16 million lives to have access to all of ASPiRA’s testing as an in-network benefit,” said Valerie Palmieri, CEO of Vermillion. “This national agreement with Cigna is a major milestone for Vermillion and patients, as OVA1 continues on its trajectory to becoming the standard of care for ovarian cancer risk assessment. OVA1 is an FDA-cleared technology to assess ovarian cancer risk in women with pelvic masses inclusive of all ages, all stages. No comparable product exists on the market, with outstanding performance in premenopausal women, all cancer types and African American women.”
About Vermillion, Inc.
Vermillion, Inc. is transforming women’s health with the discovery, development and commercialization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management and improve gynecologic health outcomes for women. OVA1®plus combines our FDA-cleared products OVA1® and OVERA® to detect risk of ovarian malignancy in women with adnexal masses. Recently launched, ASPiRA GenetiXSM testing offers both targeted and comprehensive genetic testing options with a gynecologic focus. With over 10 years of expertise in ovarian cancer risk assessment Vermillion has expertise in cutting-edge research to inform our next generation of products. Our focus is on delivering products that allow healthcare providers to stratify risk, facilitate early detection and optimize treatment plans. Visit our website for more information about our products at www.vermillion.com.
Recent AWH News
- Aspira Women’s Health Enhances its Commercial Offering with the Formal Launch of Longitudinal Monitoring Feature of OvaWatch • GlobeNewswire Inc. • 05/02/2024 12:00:00 PM
- Aspira Women’s Health Announces Anthem Blue Cross to Provide Coverage for OvaSuite(SM) in California • GlobeNewswire Inc. • 04/09/2024 12:00:00 PM
- Aspira Women’s Health Reports Fourth Quarter and Full Year 2023 Financial Results • GlobeNewswire Inc. • 03/28/2024 11:30:00 AM
- Aspira Women’s Health Announces New Time for its Fourth Quarter and 2023 Year End Earnings Results and Call • GlobeNewswire Inc. • 03/25/2024 12:00:00 PM
- Aspira Women’s Health to Present at the MedInvest Biotech & Pharma Investor Conference • GlobeNewswire Inc. • 03/21/2024 12:00:00 PM
- Aspira Women’s Health Expands Senior Leadership Team with the Addition of Sandra Milligan, M.D., J.D. as President • GlobeNewswire Inc. • 03/18/2024 12:00:00 PM
- Aspira Women’s Health to Announce Fourth Quarter and 2023 Year End Earnings Results and Host a Conference Call on Thursday, March 28, 2024 • GlobeNewswire Inc. • 03/11/2024 12:00:00 PM
- Aspira Women’s Health to Present at The Cancer Advocacy Group of Louisiana’s 3rd Annual NeauxCancer Conference • GlobeNewswire Inc. • 02/22/2024 01:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/20/2024 01:54:35 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 01:17:23 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 01:11:43 AM
- Aspira Women’s Health Announces Late-Breaking Poster Presentation at the Upcoming 71st Annual Scientific Meeting for the Society for Reproductive Investigation (SRI) • GlobeNewswire Inc. • 02/12/2024 01:00:00 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 02/07/2024 09:21:10 PM
- Aspira Women’s Health Announces OvaSuite(SM) Distribution Agreement in the Philippines • GlobeNewswire Inc. • 02/06/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/31/2024 01:31:35 AM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 01/26/2024 10:25:56 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 01/26/2024 10:19:59 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 01/26/2024 10:12:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/25/2024 10:31:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/05/2024 09:39:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/27/2023 09:41:58 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 12/26/2023 10:17:07 PM
- Aspira Women’s Health to Host R&D Day With Updates on the Development of the Company's Ovarian Cancer and Endometriosis Tests on January 4, 2024 • GlobeNewswire Inc. • 12/19/2023 01:00:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM